Integration of magnetic resonance imaging (MRI) and other imaging modalities is promising to furnish complementary information for accurate
cancer diagnosis and imaging-guided
therapy. However, most
gadolinium (Gd)-
chelator MR
contrast agents are limited by their relatively low relaxivity and high risk of released-Gd-
ions-associated toxicity. Herein, a radionuclide-64 Cu-labeled
doxorubicin-loaded
polydopamine (PDA)-
gadolinium-metallofullerene core-satellite nanotheranostic agent (denoted as CDPGM) is developed for MR/photoacoustic (PA)/positron emission tomography (PET) multimodal imaging-guided combination
cancer therapy. In this system, the near-infrared (NIR)-absorbing PDA acts as a platform for the assembly of different moieties; Gd3 N@C80 , a kind of
gadolinium metallofullerene with three Gd
ions in one
carbon cage, acts as a satellite anchoring on the surface of PDA. The as-prepared CDPGM NPs show good biocompatibility, strong NIR absorption, high relaxivity (r 1 = 14.06 mM-1 s-1 ), low risk of release of Gd
ions, and NIR-triggered drug release. In vivo MR/PA/PET multimodal imaging confirms effective
tumor accumulation of the CDPGM NPs. Moreover, upon NIR
laser irradiation, the
tumor is completely eliminated with combined chemo-
photothermal therapy. These results suggest that the CDPGM NPs hold great promise for
cancer theranostics.